Prospective identification of tumorigenic breast cancer cells

By M. Al-Hajj, M. Wicha, Adalberto Benito-Hernández, S. Morrison, M. Clarke. Proceedings of the National Academy of Sciences of the United States of America, 2003

10,686 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/1b4a7c4631dbcae0d86dbf9e49bb13f78e1df97a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Weinberg
2. Zena Werb
3. V. Plaks
4. Niwen Kong
5. J. Massagué
6. Howard Y. Chang
7. J. Dick
8. M. Clarke

In Immunology

1. R. Weinberg
2. Jane E. Visvader
3. J. Dick
4. M. Clarke
5. M. Wicha
6. Charles M. Perou
7. Aleix Prat
8. S. Morrison

In Oncology

1. R. Weinberg
2. Zena Werb
3. Jane E. Visvader
4. Thomas Brabletz
5. D. Hanahan
6. V. Plaks
7. J. Massagué
8. K. Polyak

Citations in the corpus

• LKB1 modulates lung cancer differentiation and metastasis (2007, neutral): “Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 o”
• The epigenomics of cancer. (2007, background): “an old, but still vital concept, that each patient’s tumor is a heterogeneous population of cells, some of which have more tumorigenic and metastatic potential than others (Al-Hajj et al., 2003).”
• Cancer stem cells: an old idea--a paradigm shift. (2006, background): “As few as 200 of these cells, which comprise between 1% and 10% of the total cell population, are able to form tumors when implanted in NOD/SCID mice (30).”
• Identification of miR-34a as a potent inhibitor of prostate cancer progenitor cells and metastasis by directly repressing CD44 (2011, neutral): “CSCs in many tumors—including cancers of the breas”
• The therapeutic promise of the cancer stem cell concept. (2010, background): “tial in human breast cancer samples (30).”
• Oxidative stress, inflammation, and cancer: how are they linked? (2010, background): “The first conclusive evidence for CSCs was published in 1997 [286], and to date CSCs have been isolated from both leukemias and a variety of solid tumors, including breast, brain, pancreatic, prostrate, ovary, and colon cancers [287-293].”
• The Role of Snail in EMT and Tumorigenesis (2013, background): “Such CSCs have been identified from several human tumors, including human acute myeloid leukemia malignancies, breast tumors, colon tumors, among others [89-91].”
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, positive): “Biology of cancer cells with special/unique metastatic potential: new targets for therapy The hypothesis that a subset of tumor cells (‘tumor stem cells’) are responsible for invasion and metastases, while other tumor cells are not tumorigenic, is supported by experiments on human breast cancer cell”
• Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. (2009, background): “CD44 has been used to enrich for putative cancer stem cells in other types of solid cancer, such as breast, head and neck, and pancreas and prostate (Al-Hajj et al., 2003; Patrawala et al., 2006; Li et al., 2007; Prince et al., 2007).”
• Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment (2018, background): “Several cell surface markers have been verified to identify CSCenriched populations, such as CD133, CD24, CD44, EpCAM (epithelial cell adhesion molecule), THY1, ABCB5 (ATP-binding cassette B5), and CD200 [27, 32, 34, 52].”
• Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma (2011, neutral): “ectal and prostate cancers [194-197].”
• Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis (2015, background): “CD24+CD44+ cells can have up to ten times higher mammosphere initiating capacity, and can form more aggressive tumors than CD44+/CD24- cells (16,65) that have been traditionally considered to be CSCs (159). CD24+CD44+ cells are present in multiple cell lines belonging to the luminal and basal-like s”
• Targeting cancer stem cell pathways for cancer therapy (2020, background): “Activation of the RAS/MAPK (mitogenactivated protein kinase) signaling pathway transforms nontumorigenic CD44/CD24 breast cancer cells into tumorigenic CD44/CD24 breast cancer cells.(29) A study showed that CSCs are closely related to EMT, and EMT is likely to be the basis for tumor invasion and met”
• In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. (2003, background): “Indeed, we have recently identified a tumorigenic population of cells in human breast cancers with " stem cell " properties (Al-Hajj et al. 2003).”